These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15256332)

  • 1. Clinical use of teriparatide in the real world: initial insights.
    Miller PD; Bilezikian JP; Deal C; Harris ST; Ci RP
    Endocr Pract; 2004; 10(2):139-48. PubMed ID: 15256332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?
    Girotra M; Rubin MR; Bilezikian JP
    Treat Endocrinol; 2006; 5(6):347-58. PubMed ID: 17107220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of PTH in the treatment of osteoporosis.
    Borba VZ; Mañas NC
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis.
    Holick MF
    South Med J; 2005 Nov; 98(11):1114-7. PubMed ID: 16353381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of parathyroid hormone in the treatment of osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anabolic skeletal therapy for osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anabolic agents: a new chapter in the management of osteoporosis.
    Khan AW; Khan A
    J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone anabolic agents: the unanswered queries.
    Adami S; Viapiana O; Gatti D
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):257-9. PubMed ID: 15228496
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
    Shen Y; Gray DL; Martinez DS
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone anabolic treatment with Teriparatide].
    Lamy O
    Ther Umsch; 2012 Mar; 69(3):187-91. PubMed ID: 22403112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.